Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Muscle-invasive bladder cancer: palliative radiotherapy outcomes

Aekta Sharma, Amarnath Challapalli and Amit Bahl
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.19-2-s61
Clin Med March 2019
Aekta Sharma
ABristol Medical School, University of Bristol, Bristol, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amarnath Challapalli
BBristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amit Bahl
BBristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Aims

A retrospective audit to assess outcomes in patients with muscle-invasive bladder cancer treated with palliative radiotherapy.

Methods

61 patients were treated with palliative radiotherapy between January 2011 and December 2013. The following data were collected: date of diagnosis, cystoscopy findings, date of referral for radiotherapy, dose and fractionation and acute toxicity, follow-up cystoscopy and date of disease progression (if applicable) and date of death. Data such as WHO performance status and symptoms prior to and following radiotherapy were retrospectively assessed from case notes and clinic letters. Toxicity was assessed using the Radiation Therapy Oncology Group scoring system side effects of radiotherapy. Problems collecting data included date of transurethral resection of bladder tumour (TURBT) not documented (6/61), no histology report (28/61), no cystoscopy report (11/61), and 56 patients did not have post-radiotherapy cystoscopy for the following reasons: passed away (26), not documented (23), patient declined (12). Audit standards are outlined in Table 1.

View this table:
  • View inline
  • View popup
Table 1.

Audit standards

Results

The median age (range) was 80 (34–99) years, the majority of the patients (100/130; 77%) were male and with a WHO performance status of 2 or greater. 97% of patients had radiotherapy within 31 days of the first decision to treat. Palliative radiotherapy resolved haematuria in 84%, pain and frequency in 62%, and nocturia in 86% of patients. Three patients (5%) had grade 3 acute urinary toxicity but no patients had grade 3 bowel toxicity. The most regularly used schedule was 21 Gray / three fractions / 1 week (34%), followed by 36 Gray / six fractions / 6 weeks(21%). The median survival of patients in our cohort was 7 months.

Conclusions

We have shown that the time between decision to treat and radiotherapy treatment was within 31 days, 97% of the time. Palliative radiotherapy aids symptom resolution in the majority of the patients, in line with that reported in literature. We have also concluded that haematuria is resolved much more easily than dysuria and frequency. Therefore, palliative radiotherapy is safe with no significant grade >3 toxicity.

Conflict of interest statement

No conflicts of interest to declare.

  • © Royal College of Physicians 2019. All rights reserved.
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Muscle-invasive bladder cancer: palliative radiotherapy outcomes
Aekta Sharma, Amarnath Challapalli, Amit Bahl
Clinical Medicine Mar 2019, 19 (Suppl 2) 61; DOI: 10.7861/clinmedicine.19-2-s61

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Muscle-invasive bladder cancer: palliative radiotherapy outcomes
Aekta Sharma, Amarnath Challapalli, Amit Bahl
Clinical Medicine Mar 2019, 19 (Suppl 2) 61; DOI: 10.7861/clinmedicine.19-2-s61
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Aims
    • Methods
    • Results
    • Conclusions
    • Conflict of interest statement
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Haemopoietic stem cell transplantation is a curative treatment option with minimal transplant-related complications for patients with severe Glanzmann's thrombasthenia
  • The monitoring and incidence of hyperglycaemia in inflammatory bowel disease patients treated with intravenous steroids
  • Clinical dynamics of nephropathy in patients with diabetes mellitus type 2 and concomitant essential hypertensive disease
Show more Clinical

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians